SCHEMBL21167668

SCHEMBL21167668

COC(=O)c1cnn2ccc(CNc3nc(-c4cnn(CCO)c4)cnc3N)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.41
MET P08581 3/20 0.40
LDHA P00338 1/20 0.40
LDHB P07195 1/20 0.40
SYK P43405 1/20 0.39
EGFR P00533 1/20 0.39
IKBKE Q14164 4/20 0.39
TBK1 Q9UHD2 4/20 0.39
FGFR1 P11362 5/20 0.37
FGFR3 P22607 5/20 0.37
KDR P35968 5/20 0.37
KIT P10721 1/20 0.36
FGFR2 P21802 2/20 0.36
FGFR4 P22455 2/20 0.36
FLT3 P36888 1/20 0.36
CTSL P07711 1/20 0.36
TYRO3 Q06418 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
JAK3 P52333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22475890 0.85 MET (0.43) CSF1RMETLDHALDHBSYK
SCHEMBL23127845 0.85 MET (0.43) CSF1RMETLDHALDHBSYK
SCHEMBL21167664 0.84 EGFR (0.40) METEGFRIKBKETBK1FGFR1
SCHEMBL21167564 0.81 MET (0.59) CSF1RMETLDHALDHBEGFR
SCHEMBL16882496 0.79 MET (0.45) METSYKFGFR1FGFR3KDR
SCHEMBL12689736 0.78 MET (0.66) MET
SCHEMBL22475682 0.78 MET (0.42) METSYKFGFR1FGFR3KDR
SCHEMBL24591095 0.78 MET (0.40) METSYKFGFR1FGFR3KDR
SCHEMBL21167473 0.75 MET (0.47) CSF1RMETLDHALDHBSYK
SCHEMBL23127964 0.75 CSF1R (0.50) CSF1RMETLDHALDHBSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3795573-B1 CERTAIN TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR HUTCHISON MEDIPHARMA LTD (CN) 2022-07-06 EP disclosed
EP-3511330-A1 SYNTHETIC INTERMEDIATE USEFUL IN THE PREPARATION OF TRIAZOLOPYRIDINE C-MET INHIBITORS Hutchison Medipharma Limited (CN) 2019-07-17 EP disclosed